It was studied in the 1950s for its anticonvulsant properties, as a treatment for generalised tonic-clonic seizures. It was not effective for absence seizures.
Interest in the drug resumed in the 1990s for its psychiatric properties as an adjunct in the treatment of schizophrenia.
Side effects are uncommon but include stomach pain, nervousness, giddiness, skin rash and leukopenia. It is counter-indicated in breast feeding as it is passed in the milk.
Administration and pharmacology
Administration is oral, though it has an unpleasant taste. It is quickly absorbed and elimination is renal and complete within 48 hours. Beclamide is possibly metabolized to 3-chloropropanoic acidin vivo, which binds to the GHB receptor.
^Ahmadi M, Nicholls PJ, Smith HJ, Spencer PS, Preet-Ryatt MS, Spragg BP (October 1995). "Metabolism of beclamide after a single oral dose in man: quantitative studies". The Journal of Pharmacy and Pharmacology. 47 (10): 876–8. doi:10.1111/j.2042-7158.1995.tb05757.x. PMID8583359.
^Raptis C, Garcia-Borreguero D, Weber MM, Dose M, Bremer D, Emrich HM (February 1990). "Anticonvulsants as adjuncts for the neuroleptic treatment of schizophrenic psychoses: a clinical study with beclamide". Acta Psychiatrica Scandinavica. 81 (2): 162–7. doi:10.1111/j.1600-0447.1990.tb06472.x. PMID2183543.
The Medical Treatment of Epilepsy by Stanley R Resor. Published by Marcel Dekker (1991). ISBN0-8247-8549-5.